Tumor vasculature as a therapeutic target in non-small cell lung cancer;A daganatos érhálózat mint terápiás célpont nem kissejtes tüdorákban

Magyar Onkologia

Volumn 52, Issue 3, 2008, Pages 247-259

  Döme, Balázs ^a,c   Magyar, Melinda ^b,c  

^a Orszagos Koranyi Tbc es Pulmonologiai Intezet   (Hungary)

^b XI Tüdogyógyászati Osztály ^*  (Hungary)

^c Tumorbiológiai Osztály   (Hungary)

Author keywords

Angiogenesis; Lung cancer

Indexed keywords

4 ((4 FLUORO 2 METHYL 1H INDOL 5 YL)OXY) 6 METHOXY 7 (3 (PYRROLIDIN 1 YL)PROPOXY)QUINAZOLINE; 4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-(3-(PYRROLIDIN-1-YL)PROPOXY)QUINAZOLINE; 5,6 DIMETHYLXANTHENONEACETIC ACID; 5,6-DIMETHYLXANTHENONEACETIC ACID; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; AXITINIB; BENZENESULFONIC ACID DERIVATIVE; BEVACIZUMAB; DRUG DERIVATIVE; HYBRID PROTEIN; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; MOTESANIB; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; NICOTINAMIDE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SORAFENIB; SULFONAMIDE; TUMOR MARKER; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE;

BLOOD; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BENZENESULFONATES; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; LUNG NEOPLASMS; NIACINAMIDE; PIPERIDINES; PYRIDINES; QUINAZOLINES; RECOMBINANT FUSION PROTEINS; SULFONAMIDES; TUMOR MARKERS, BIOLOGICAL; XANTHONES;

EID: 58149235293     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: 10.1556/MOnkol.52.2008.3.2     Document Type: Article

References (123)

1. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9:1370-1376, 2003
2. Amin DN, Bielenberg DR, Lifshits E, et al. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res 18 Mar, 2008 (Epub ahead of print)
3. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997
4. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15:102-111, 2005
5. Benjamin LE, Golffanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159-165, 1999
6. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 29:78-86, 2002
7. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000
8. Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer 8(Suppl 2):S79-85, 2007
9. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19:189-195, 1999
10. Chen JJ, Yao PL, Yuan A, et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 9:729-737, 2003
11. Decaussin M, Sartelet H, Robert C, et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 188:369-377, 1999
12. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-Agent or a 2-Agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-Analysis. JAMA 292:470-484, 2004
13. Delmotte P, Martin B, Paesmans M, et al. VEGF and survival of patients with lung cancer: a systematic literature review and metaanalysis. Rev Ma Respir 19:577-584, 2002
14. Dome B, Dobos J, Tovari J, et al. Circulating bone marrow-derived endothelial progenitor cells: Characterization, mobilization, and therapeutic considerations in malignant disease. Cytometry A 73:186-193, 2008
15. Dome B, Hendrix MJ, Paku S, et al. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 170:1-15, 2007
16. Dome B, Timar J, Dobos J, et al. Identification and clinical signifi-cance of circulating endothelial progenitor cells in human nonsmall cell lung cancer. Cancer Res 66:7341-7347, 2006
17. Dowlati A, Gray R, Johnson DH, et al. Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel + bevacizumab in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 24S:7027, 2006
18. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16:558-565, 2005
19. Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25:4033-4042, 2007
20. Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 18:1007-1021, 2004
21. Fontanini G, Boldrini L, Chinè S, et al. Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br J Cancer 79:363-369, 1999
22. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3:861-865, 1997
23. Fox E, Maris JM, Widemann BC, et al. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 12:4882-4887, 2006
24. Fujimoto K, Abe T, Müller NL, et al. Small peripheral pulmonary carcinomas evaluated with dynamic MR imaging: correlation with tumor vascularity and prognosis. Radiology 227:786-793, 2003
25. Fujita S, Nagamachi S, Nishii R, et al. Relationship between cancer cell proliferation, tumour angiogenesis and 201Tl uptake in nonsmall cell lung cancer. Nucl Med Commun 27:989-997, 2006
26. Furstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94:524-531, 2006
27. Garanger E, Boturyn D, Dumy P. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem 7:552-558, 2007
28. Gatzemeier U, Blumenschein G, Fosella F, et al. Phase II trial of single-Agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 24:18S:7002, 2006
29. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33:392-406, 2006
30. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001
31. Goss GD, Laurie S, Shepherd F, et al. Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group. J Clin Oncol 25(18S):7649, 2007
32. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539-4544, 2006
33. Guo J, Higashi K, Ueda Y, et al. Microvessel density: correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J Nucl Med 47:419-425, 2006
34. Haines IE, Miklos GL, Rossi A, et al. Paclitaxel plus bevacizumab for metastatic breast cancer. N Eng J Med 358:1637-1638, 2008
35. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8:72-79, 2001
36. Hande KR, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 12:2834-2840, 2006
37. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25:4743-4750, 2007
38. Heymach J, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or in combination with carboplatin and paclitaxel as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 25(18S):7544, 2007
39. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebocontrolled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25:4270-4277, 2007
40. Hilbe W, Dirnhofer S, Oberwasserlechner F, et al. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 57:965-969, 2004
41. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62:2554-2560, 2002
42. Ho JW, Pang RW, Lau C, et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 44:836-843, 2006
43. http://clinicaltrials.gov/ct2/show/NCT00073151?term=ABT- 751+lung&rank=2
44. http://clinicaltrials.gov/ct2/show/NCT00113438?term=ca4p&rank=1
45. http://clinicaltrials.gov/ct2/show/NCT00297089?term=ABT- 751+lung&rank=3
46. http://clinicaltrials.gov/ct2/show/NCT00354562?term=ABT- 751+lung&rank=1
47. http://www.gene.com/gene/news/press-releases/display.do?meth od=detail&id=11207
48. http://www.press.bayer.com/baynews/baynews.nsf/id/ 7F2163C8C6C18519C12573F30051050E?Open&ccm=001
49. Hu J, Bianchi F, Ferguson M, et al. Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer. Oncogene 24:1212-1219, 2005
50. Hudis CA. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 19(4 Suppl 3):26-31, 2005
51. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
52. Igreja C, Courinha M, Cachaco AS, et al. Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients. Haematologica 92:469-477, 2007
53. Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg 25:443-448, 2004
54. Jain RK. Normalizing tumor vasculature with anti-Angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989, 2001
55. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24-40, 2006
56. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004
57. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
58. Leighl NB, Paz-Arez L, Douillard JL, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 23:2831-2839, 2005
59. Li B, Sharpe EE, Maupin AB, et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 20:1495-1497, 2006
60. Li X, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest 115:118-127, 2005
61. Li Y, Yang ZG, Chen TW, et al. Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT. Lung Cancer 61:44-53, 2008
62. Liu B, Barrett T, Choyke P, et al. A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol 24(18S):17119, 2006
63. Llevadot J, Murasawa S, Kureish Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108:399-405, 2001
64. Loupakis F, Falcone A, Masi G, et al. Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol 25:1816-1818, 2007
65. Ma SH, Xu K, Xiao ZW, et al. Peripheral lung cancer: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and cyclin D1 expression. Clin Imaging 31:165-177, 2007
66. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, doubleblind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 25(18S):7514, 2007
67. Masood R, Cai J, Zheng T, et al. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98:1904-1913, 2001
68. Massa M, Rosti V, Ramajoli I, et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 23:5688-5695, 2005
69. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394:287-291, 1998
70. McKeage MJ. Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). J Clin Oncol 24(18S):7102, 2006
71. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19:1195-1206, 2001
72. Moore MA, Hattori K, Heissig B, et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann NY Acad Sci 938:36-47, 2001
73. Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4- Acetic acid. Radiat Res 156:503-509, 2001
74. Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part double-blind randomized phase II trial. J Clin Oncol 24(18S):7000, 2006
75. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605, 2003
76. Olivero M, Rizzo M, Madeddu R, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human nonsmall-cell lung carcinomas. Br J Cancer 74:1862-1868, 1996
77. Ozawa Y, Sugi NH, Nagasu T, et al. E7070, a novel sulfonamide agent with potent antitumor activity in vitro and in vivo. Eur J Cancer 37:2275-2282, 2001
78. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005
79. Passalidou E, Trivella M, Singh N, et al. Vascular phenotype in angiogenic and non-Angiogenic lung non-small cell carcinomas. Br J Cancer 86:244-249, 2002
80. Patterson DM, Rustin GJ. Vascular damaging agents. Clin Oncol (R Coll Radiol) 19:443-456, 2007
81. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530, 1997
82. Pezzella F, Pastorino U, Tagliabue E, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neoangiogenesis. Am J Pathol 151:1417-1423, 1997
83. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330-353, 2004
84. Pircher A, Kähler CM, Skvortsov S, et al. Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: a methodological challenge and an ongoing debate on the clinical relevance. Oncol Rep 19:345-352, 2008
85. Provenzale JM. Imaging of angiogenesis: clinical techniques and novel imaging methods. AJR Am J Roentgenol 188:11-23, 2007
86. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969, 1997
87. Riely GJ, Miller VA. Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res 13:4623-4627, 2007
88. Sánchez-Elsner T, Botella LM, Velasco B, et al. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 277:43799-43808, 2002
89. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
90. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 9:571-579, 2003
91. Santoro M, Melillo RM, Carlomagno F, et al. Molecular mechanisms of RET activation in human cancer. Ann NY Acad Sci 963:116-121, 2002
92. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
93. Schiller JH, Larson T, Ou SI, et al. Efficacy and safety of axitinib (AG-013736; AG) in patients with advanced non-small cell lung cancer (NSCLC): A phase II trial. J Clin Oncol 25(18S):7507, 2007
94. Seeger FH, Haendeler J, Walter DH, et al. p38 mitogen-Activated protein kinase downregulates endothelial progenitor cells. Circulation 111:1184-1191, 2005
95. Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res 312:651-658, 2006
96. Seto T, Higashiyama M, Funai H, et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 53:91-96, 2006
97. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:1785-1787, 2006
98. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
99. Shiraga M, Yano S, Yamamoto A, et al. Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines. Cancer Res 62:5967-5973, 2002
100. Siemann DW, Bibby MC, Dark GG, et al. Differentiation and defi-nition of vascular-Targeted therapies. Clin Cancer Res 11:416-420, 2005
101. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99:1-6, 2002
102. Siim BG, Lee AE, Shalal-Zwain S, et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-Acetic acid (DMXAA). Cancer Chemother Pharmacol 51:43-52, 2003
103. Socinski MA, Novello S, Sanchez JM, et al. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. J Clin Oncol 24(18S):7001, 2006
104. Strehlow K, Werner N, Berweiler J, et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107:3059-3065, 2003
105. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369-3372, 2001
106. Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thoracic Oncol 1:1002-1009, 2006
107. Tanaka F, Ishikawa S, Yanagihara K, et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 62:7124-7129, 2002
108. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
109. Tímár J, Döme B. Antiangiogenic drugs and tyrosine kinases. Anticancer Agents Med Chem 2008 (in press
110. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109:2058-2067, 2004
111. Vignaud JM, Marie B, Klein N, et al. The role of platelet-derived growth factor production by tumor-Associated macrophages in tumor stroma formation in lung cancer. Cancer Res 54:5455-5463, 1994
112. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655, 2002
113. Wierzbowska A, Robak T, Krawczynska A, et al. Circulating endothelial cells in patients with acute myeloid leukemia. Eur J Haematol 75:492-497, 2005
114. Wilhelm SM, Carter M, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004
115. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
116. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23:8136-8139, 2005
117. www.oxigene.com/vascular/vascular.asp#ZYBRESTAT
118. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
119. Yee KW, Hagey A, Verstovsek S, et al. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 11:6615-6624, 2005
120. Yokoyama Y, Dhanabal M, Griffioen AW, et al. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 60:2190-2196, 2000
121. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and signifi-cance. Blood 105:3286-3294, 2005
122. Zhang L, Chen J, Ke Y, et al. Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 3:68, 2005
123. Zheng PP, Hop WC, Luider TM, et al. Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann Neurol 62:40-48, 2007